Z4D.SI stock +11.11% intraday on 17 Mar 2026: S$0.01 hold or breakout

Z4D.SI stock jumped 11.11% intraday on 17 Mar 2026, trading at S$0.01 on the Singapore Exchange (SES). The move came on 100,000 shares, making Medi Lifestyle Limited one of today’s small-cap movers in the healthcare sector. Investors are watching the S$0.01 level as immediate support. We review fundamentals, technicals, Meyka AI grading, and model forecasts to frame short-term trade setups and longer-term outlook.

Intraday price action and volume

Medi Lifestyle Limited (Z4D.SI) opened at S$0.01 and matched a day high of S$0.01 on 17 Mar 2026. Volume for the session was 100,000 shares. The intraday price gain of 11.11% occurred despite average volume of 238,200, suggesting attention from active traders rather than broad institutional flows.

Z4D.SI stock fundamentals and valuation

Medi Lifestyle Limited reports EPS of -0.01 and a PE of -0.90, reflecting negative earnings. Market capitalisation sits at S$1,530,000.00 with 170,000,000 shares outstanding. Price-to-sales is 0.87, and price averages show 50-day: S$0.01 and 200-day: S$0.01. Current ratio and cash metrics indicate tight liquidity, with cash per share of S$0.00 and current ratio about 0.52.

Z4D.SI stock technicals and short-term setup

Technicals show a subdued momentum picture. RSI is 38.34, CCI is -155.56, and ADX is 31.45, indicating a strong underlying trend but oversold momentum. Key support is S$0.01. A daily close above S$0.01 with higher volume would suggest a short-term breakout. Watch average volume and order book depth on SES for confirmation.

Meyka AI grade and model forecast

Meyka AI rates Z4D.SI with a score out of 100. Meyka AI rates Z4D.SI with a score of 66.66 out of 100, Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly: S$0.01 and yearly: S$0.02, implying 104.56% upside versus the current S$0.01. Forecasts are model-based projections and not guarantees.

Sector context and catalysts

Medi Lifestyle sits in Healthcare, Medical – Care Facilities, on the SES in Singapore. The healthcare sector YTD is slightly negative, and top peers trade with higher liquidity. Near-term catalysts include operational updates for NADORA and Back to Life services, commodity trading results, and any recruitment or BPO contract announcements. Lack of scheduled earnings before August 2025 limits immediate fundamental triggers.

Risks, liquidity and trading considerations

Key risks include negative earnings, limited free cash flow, and low market capitalisation of S$1,530,000.00. Average volume is 238,200, so liquidity can swing widely. Short-term traders should size positions carefully and use stop-losses around S$0.01. Longer-term investors must monitor quarterly performance and cash conversion improvements.

Final Thoughts

Z4D.SI stock closed the intraday session at S$0.01 on 17 Mar 2026 after a 11.11% lift on 100,000 shares. Fundamentals show negative EPS and constrained liquidity, while technicals indicate oversold momentum with potential for a short squeeze if volume rises. Meyka AI’s forecast model projects a one-year figure near S$0.02, implying 104.56% upside versus the current S$0.01. We set a base price target of S$0.02 and a more optimistic scenario target of S$0.05 for multi-year recovery, subject to improved earnings and liquidity. These figures reflect model outputs and analyst consensus inputs, not guarantees. Traders should treat Z4D.SI as speculative and size positions accordingly. For reference, visit the company site Medi Lifestyle website and session comparables on Investing.com compare. Meyka AI, our AI-powered market analysis platform, supplied the proprietary grade and forecast data.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.